文献速递肿瘤 PET/CT

治疗前18F-FDG PET基于病灶的影像组学特征可预测淋巴瘤患者对伊布替尼的治疗反应

Lesion-Based Radiomics Signature in Pretherapy 18F-FDG PET Predicts Treatment Response to Ibrutinib in Lymphoma.
PubMed 文献 · Clin Nucl Med · 2022-01-01

本研究回顾性分析169例淋巴瘤患者2441个病灶,基于治疗前18F-FDG PET提取影像组学特征构建预测伊布替尼治疗反应的模型。影像组学模型预测反应的ROC AUC为0.860(敏感度92.9%,特异度81.4%,P<0.001),优于SUVmax、代谢肿瘤体积、总病灶糖酵解及三者复合模型;患者水平ROC AUC为0.811(P=0.007)。

要点

  • 基于病灶的影像组学模型预测伊布替尼反应ROC AUC为0.860,敏感度92.9%,特异度81.4%。
  • 该模型优于SUVmax(AUC 0.519)、代谢肿瘤体积(AUC 0.579)和总病灶糖酵解(AUC 0.576)。
  • 模型将准确预测伊布替尼敏感病灶的概率从84.8%(检验前)提升至96.5%(检验后)。

核心结论

  • 研究开发并验证了基于治疗前PET的影像组学模型,用于预测淋巴瘤患者对伊布替尼的治疗反应。

研究设计与样本

  • 回顾性研究,纳入169例淋巴瘤患者共2441个病灶,基于治疗前18F-FDG PET图像进行病灶勾画和分割以提取影像组学特征。
  • 病灶水平和患者水平的伊布替尼反应性均依据Lugano分类回顾性判定。
  • 构建影像组学模型预测伊布替尼反应,并在测试队列中独立评估其预后意义,与传统PET指标(SUVmax、代谢肿瘤体积、总病灶糖酵解)进行比较。

主要发现

  • 影像组学模型预测伊布替尼反应的ROC AUC为0.860(敏感度92.9%,特异度81.4%;P<0.001)。
  • SUVmax的ROC AUC为0.519(P=0.823),代谢肿瘤体积为0.579(P=0.412),总病灶糖酵解为0.576(P=0.199),三者复合模型为0.562(P=0.046)。
  • 影像组学模型将准确预测伊布替尼敏感病灶的概率从84.8%(检验前)提升至96.5%(检验后)。
  • 患者水平模型性能ROC AUC=0.811(P=0.007),优于传统PET指标。
  • 模型在治疗亚组中验证显示稳健性:一线治疗ROC AUC=0.916(P<0.001)对比二线及以上治疗ROC AUC=0.842(P<0.001);单药治疗ROC AUC=0.931(P<0.001)对比多药治疗ROC AUC=0.824(P<0.001)。

关键数值与推荐

  • 病灶反应性依据Lugano分类判定。
  • 影像组学模型预测反应ROC AUC=0.860(敏感度92.9%,特异度81.4%;P<0.001)。
  • 患者水平模型ROC AUC=0.811(P=0.007)。
  • 一线治疗亚组ROC AUC=0.916(P<0.001),二线及以上治疗亚组ROC AUC=0.842(P<0.001)。
  • 单药治疗亚组ROC AUC=0.931(P<0.001),多药治疗亚组ROC AUC=0.824(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to develop a pretherapy PET/CT-based prediction model for treatment response to ibrutinib in lymphoma patients. PATIENTS AND METHODS: One hundred sixty-nine lymphoma patients with 2441 lesions were studied retrospectively. All eligible lymphomas on pretherapy 18F-FDG PET images were contoured and segmented for radiomic analysis. Lesion- and patient-based responsiveness to ibrutinib was determined retrospectively using the Lugano classification. PET radiomic features were extracted. A radiomic model was built to predict ibrutinib response. The prognostic significance of the radiomic model was evaluated independently in a test cohort and compared with conventional PET metrics: SUVmax, metabolic tumor volume, and total lesion glycolysis. RESULTS: The radiomic model had an area under the receiver operating characteristic curve (ROC AUC) of 0.860 (sensitivity, 92.9%, specificity, 81.4%; P < 0.001) for predicting response to ibrutinib, outperforming the SUVmax (ROC AUC, 0.519; P = 0.823), metabolic tumor volume (ROC AUC, 0.579; P = 0.412), total lesion glycolysis (ROC AUC, 0.576; P = 0.199), and a composite model built using all 3 (ROC AUC, 0.562; P = 0.046). The radiomic model increased the probability of accurately predicting ibrutinib-responsive lesions from 84.8% (pretest) to 96.5% (posttest). At the patient level, the model's performance (ROC AUC = 0.811; P = 0.007) was superior to that of conventional PET metrics. Furthermore, the radiomic model showed robustness when validated in treatment subgroups: first (ROC AUC, 0.916; P < 0.001) versus second or greater (ROC AUC, 0.842; P < 0.001) line of defense and single treatment (ROC AUC, 0.931; P < 0.001) versus multiple treatments (ROC AUC, 0.824; P < 0.001). CONCLUSIONS: We developed and validated a pretherapy PET-based radiomic model to predict response to treatment with ibrutinib in a diverse cohort of lymphoma patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jimenez JE, Dai D, Xu G, et al. Lesion-Based Radiomics Signature in Pretherapy 18F-FDG PET Predicts Treatment Response to Ibrutinib in Lymphoma. Clin Nucl Med. 2022. PMID: 35020640. doi:10.1097/RLU.0000000000004060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。